- Home
- IRWD
IRWD
Ironwood Pharmaceuticals Inc.
as 02-21-2025 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Ironwood Pharmaceuticals Inc. IRWD prepares to release earnings report on 27 Feb 2025.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2010 |
| Target Price: | $12.00 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.59 - $15.26 | Next Earning Date: | 02-27-2025 |
| Revenue: | $378,418,000 | Revenue Growth: | -12.48% |
| Revenue Growth (this year): | -18.28% | Revenue Growth (next year): | -18.93% |
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| John Minardo | IRWD | Chief Legal Officer | Feb 10 '25 | Sell | $1.76 | 38,938 | $68,530.88 | 408,132 | |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | Feb 10 '25 | Sell | $1.76 | 139,064 | $244,752.64 | 1,160,634 | |
| Shetzline Michael | IRWD | SVP, CMO, Head-Res&Drug | Feb 10 '25 | Sell | $1.76 | 41,269 | $72,633.44 | 554,007 | |
| Silver Ronald | IRWD | Principal Accounting Officer | Feb 10 '25 | Sell | $1.76 | 12,048 | $21,204.48 | 279,655 | |
| Martini Gregory S. | IRWD | Chief Financial Officer | Feb 10 '25 | Sell | $1.76 | 12,052 | $21,211.52 | 183,810 |
Latest Ironwood Pharmaceuticals Inc. News
IRWD Breaking Stock News: Dive into IRWD Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
PR Newswire
17 days ago
Millrose Properties Set to Join S&P SmallCap 600
Argus Research
18 days ago
IRWD: Lowering target price to $2.00
MT Newswires
23 days ago
Top Midday Decliners
Zacks
23 days ago
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
MT Newswires
24 days ago
Ironwood Pharmaceuticals to Slash Half of Workforce, Drop Phase 2 Testing of Drug; Issues 2025 Outlook
Business Wire
24 days ago
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
Argus Research
25 days ago
IRWD: What does Argus have to say about IRWD?
Compare IRWD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.